Celgene Increases Japan Sales Reps As Revlimid Grows
This article was originally published in PharmAsia News
Executive Summary
Celgene Japan has increased the number of sales representatives specializing in flagship flagship multiple myeloma therapy Revlimid (lenalidomide) to 100, up from 60 sales reps at the time of launch in July 2007.